Zobrazeno 1 - 10
of 154
pro vyhledávání: '"Michelle H. Biros"'
Publikováno v:
International Journal of Emergency Medicine, Vol 14, Iss 1, Pp 1-9 (2021)
Abstract Quite a few changes and challenges have arisen in society in general as technology has advanced and the aging population has increased. These can lead to the recognition of the shortcomings of a society’s traditional systems and the variou
Externí odkaz:
https://doaj.org/article/1517d9989a1c4b0c895acb282212191d
Autor:
Michael A. Puskarich, Nathan W. Cummins, Nicholas E. Ingraham, David A. Wacker, Ronald A. Reilkoff, Brian E Driver, Michelle H. Biros, Fernanda Bellolio, Jeffrey G. Chipman, Andrew C. Nelson, Kenneth Beckman, Ryan Langlois, Tyler Bold, Matthew T. Aliota, Timothy W. Schacker, Helen T. Voelker, Thomas A Murray, Joseph S. Koopmeiners, Christopher J. Tignanelli
Publikováno v:
EClinicalMedicine, Vol 37, Iss , Pp 100957- (2021)
Background: The SARS-CoV-2 virus enters cells via Angiotensin-converting enzyme 2 (ACE2), disrupting the renin-angiotensin-aldosterone axis, potentially contributing to lung injury. Treatment with angiotensin receptor blockers (ARBs), such as losarta
Externí odkaz:
https://doaj.org/article/fd49def584d94f00b3736cdb49b13432
Autor:
Jon B. Cole, Samantha C. Lee, Marc L. Martel, Stephen W. Smith, Michelle H. Biros, James R. Miner
Publikováno v:
Western Journal of Emergency Medicine, Vol 22, Iss 2 (2020)
Externí odkaz:
https://doaj.org/article/cc8e69e82d3e4875b4083c280d81ec32
Autor:
Jon B. Cole, Samantha C. Lee, Marc L. Martel, Stephen W. Smith, Michelle H. Biros, James R. Miner
Publikováno v:
Western Journal of Emergency Medicine, Vol 21, Iss 4 (2020)
Introduction: Droperidol carries a boxed warning from the United States Food and Drug Administration for QT prolongation and torsades des pointes (TdP). After a six-year hiatus, droperidol again became widely available in the US in early 2019. With i
Externí odkaz:
https://doaj.org/article/1b80b1173556400294eecc048e8c8e78
Publikováno v:
Stroke. 54
Introduction: Enrollment in acute stroke clinical trials (ASCTs) is complex and unpredictable. Traditional staffing models (TSMs) of research coordinator coverage assign a single research coordinator to cover specific clinical trials, whereas pooled
Autor:
Michael A, Puskarich, Nicholas E, Ingraham, Lisa H, Merck, Brian E, Driver, David A, Wacker, Lauren Page, Black, Alan E, Jones, Courtney V, Fletcher, Andrew M, South, Thomas A, Murray, Christopher, Lewandowski, Joseph, Farhat, Justin L, Benoit, Michelle H, Biros, Kartik, Cherabuddi, Jeffrey G, Chipman, Timothy W, Schacker, Faheem W, Guirgis, Helen T, Voelker, Joseph S, Koopmeiners, Christopher J, Tignanelli, Nastasia, James
Publikováno v:
JAMA network open. 5(3)
SARS-CoV-2 viral entry may disrupt angiotensin II (AII) homeostasis, contributing to COVID-19 induced lung injury. AII type 1 receptor blockade mitigates lung injury in preclinical models, although data in humans with COVID-19 remain mixed.To test th
Publikováno v:
Academic Emergency Medicine. 28:421-434
BACKGROUND The optimal agent to treat acute agitation in the emergency department (ED) has not been determined. The objective of this study was to compare the effectiveness and safety of intramuscular droperidol, ziprasidone, and lorazepam for acute
Autor:
Renee D. Stapleton, Joseph P. Mizgerd, Catherine L. Hough, Niall D. Ferguson, Michelle N. Gong, Dale M. Needham, Carolyn S. Calfee, Matthew W. Semler, Theodore J. Iwashyna, Gordon R. Bernard, B. Taylor Thompson, Thomas R. Martin, Marc Moss, Shawn D. Aaron, Michelle H. Biros, Richard G. Wunderink, Elizabeth Colantuoni, Bruce D. Levy, Derek C. Angus, Neil R. Aggarwal, Roy G. Brower, Ramona O. Hopkins, Lora A. Reineck, Michael A. Matthay, Wesley H. Self, Christopher W. Seymour
Publikováno v:
Am J Respir Crit Care Med
Preventing, treating, and promoting recovery from critical illness due to pulmonary disease are foundational goals of the critical care community and the National Heart, Lung, and Blood Institute. Decades of clinical research in acute respiratory dis
Autor:
Tyler D. Bold, Justin L. Benoit, Timothy W. Schacker, Ryan A. Langlois, Faheem W. Guirgis, Helen Voelker, Dana Bryne, Joseph S. Koopmeiners, Matthew T. Aliota, Lisa H. Merck, Kartikeya Cherabuddi, Kenneth B. Beckman, James Galbraith, Ronald Reilkoff, Alan E. Jones, Chas Salmen, Lauren Page Black, Jeffrey G. Chipman, Alex Hall, Margaret Beyer, Michael A. Puskarich, Joseph Farhat, Brian W. Roberts, David A. Wacker, Andrew M South, David W. Wright, Michelle H. Biros, Brian E. Driver, Nicholas E. Ingraham, Andrew C. Nelson, Christopher J. Tignanelli, Courtney V. Fletcher, Christopher Lewandowski, Thomas A. Murray
BackgroundSARS-CoV-2 viral entry may disrupt angiotensin II (Ang II) homeostasis in part via ACE2 downregulation, potentially contributing to COVID-19 induced lung injury. Preclinical models of viral pneumonias that utilize ACE2 demonstrate Ang II ty
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::71e16121d4e69bf9372be3ecf1fb9089
https://doi.org/10.1101/2021.08.25.21262623
https://doi.org/10.1101/2021.08.25.21262623
Autor:
Ryan A. Langlois, Brian E. Driver, Nicholas E. Ingraham, David A. Wacker, Michelle H. Biros, Christopher J. Tignanelli, Joseph S. Koopmeiners, Helen Voelker, M. Fernanda Bellolio, Michael A. Puskarich, Thomas A. Murray, Tyler D. Bold, Timothy W. Schacker, Nathan W. Cummins, Jeffrey G. Chipman, Kenneth B. Beckman, Ronald Reilkoff, Matthew T. Aliota, Andrew C. Nelson
Publikováno v:
EClinicalMedicine, Vol 37, Iss, Pp 100957-(2021)
EClinicalMedicine
EClinicalMedicine
Background The SARS-CoV-2 virus enters cells via Angiotensin-converting enzyme 2 (ACE2), disrupting the renin-angiotensin-aldosterone axis, potentially contributing to lung injury. Treatment with angiotensin receptor blockers (ARBs), such as losartan